Skip to content

"Shuanggu Yitong" Acupuncture Therapy for the Clinical Study of Premature Ovarian Insufficiency

"Shuanggu Yitong" Acupuncture Therapy for the Clinical Study of Premature Ovarian Insufficiency

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000350
Enrollment
Unknown
Registered
2025-02-19
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ovarian insufficiency

Interventions

Control group: Sham acupuncture + Western medicine "Fenmuto"
Experimental group:Acupuncture + Western medicine "Fenmuto"

Sponsors

Hubei University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Women with POI aged between 20 and 40 years old; 2) Those who are willing to receive acupuncture treatment; 3) Those who have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Those with congenital reproductive organ developmental abnormalities organic lesions such as ovarian tumors or those with decreased ovarian function due to radiotherapy and chemotherapy etc; 2) Those with secondary amenorrhea caused by polycystic ovary syndrome hyperprolactinemia thyroid diseases etc; 3) Those with severe primary diseases such as heart liver kidney and hematopoietic system diseases; 4) Those with mental disorders who are unable to cooperate with treatment; 5) Those who have received acupuncture or sex hormone treatment within the last three months.

Design outcomes

Primary

MeasureTime frame
TCM syndrome score;

Secondary

MeasureTime frame
Estradiol;menstrual reting scale;Resistance Index;Interleukin-10;Peak Systolic Velocity;Anti-Müllerian hormone;luteinizing hormone;Interferon-?;Regulatory T cells;Tumor necrosis factor-a;Self-rating anxiety scale;Antral follicle count;Transforming growth factor-beta;Safety Observation Indicators (blood routine, urine routine, liver and kidney function, adverse event records);Pittsburgh sleep quality index;Helper T cells;Follicle-stimulating hormone;pulsatility index;

Countries

China

Contacts

Public ContactWAN Xiaoman

Hubei University of Chinese Medicine

1482420307@qq.com15002788376

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026